BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of Adults with Waldenström’s Macroglobulinemia

BeiGene’s European commercial team is preparing to launch BRUKINSA, the company’s first medicine submitted for marketing authorization in the EU, upon approval The CHMP recommendation is based on results from the Phase 3 ASPEN trial, in which BRUKINS...

Full "IntellAsia: Resources" article